Webinar: Machine Learning meets Degrader Design

| September 23, 2021 | Degrader, Machine Learning, Medicinal Chemistry, Technology

This video is our webinar from 23 September, held by Arjun Rao, Senior ML Researcher, about how Machine Learning meets Degrader Design. In this video, you will learn

* Why current drugs lead to 80-90 % of undruggable targets
* Why degradation might be the solution
* What is degradation?
* What is the ubiquitin-proteasome system
* How does it compare to other strategies like CRISPR-Cas9, RNAi, and inhibition?
* What is hard at developing degraders?
* What is deep learning?
* How does our deep learning pipeline work?
* How do we compare to the STOTA?
* What modules does Celeris Therapeutics have in its computer-based platform?
* How do we address degrader design with a closed-loop platform: Celeris One

The Third Wave of Degrader Discovery

Christopher Trummer

- October 25, 2021

Degrader, Machine Learning, Medicinal Chemistry, Technology

The Third Wave of Degrader Discovery Proteins occupy a special place in the biological domain as the master regulators of biochemical processes in the cell. They accomplish this as enzymes, hormones, transporters, signal transducers, and other complex molecules to ensure the cell maintains a homeostatic balance. This system, while amazingly resilient, breaks down when those […]

Why is targeted protein degradation next generation of therapeutic solutions, and how can AI help

Noah Weber

- August 24, 2021

Degrader, Machine Learning, Medicinal Chemistry, Technology

The year is 2021 and we are still not able to treat: Alzheimer’s, Huntington’s, Parkinson’s, and many other diseases WHY? Distribution of undruggable and inhibitable drugs The primary factor is that less than 20% percent of all pathogenic (disease-related proteins) are inhibitable. The rest is just undruggable. Ok, but what does that mean exactly? For […]

Noah Weber

- August 30, 2021

Longevity, Machine Learning, Technology

With the new book The Science and Technology of Growing Young by Sergey Young, we, Celeris Therapeutics, an AI company in this space, had to analyze the book through our AI lense and pose potential approaches to tackle the problems outlined in the book. “Aging, quite simply, is a loss of information”, Dr. David Sinclair If one peels […]